Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of TQ05105
NCT07293390Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rovadicitinib in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Radioactivity excretion rate at 504 hours, Peak concentration at 336 hours and 1 more. Started Mar 2024; status: completed.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07293390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293390.